Huahai Pharmaceutical receives approval for tolvaptan tablets
Zhejiang Huahai Pharmaceutical (SSE:600521) announced that it has received a drug registration certificate from the National Medical Products Administration for its Tolvaptan Tablets. The drug, categorized as a Class 4 chemical drug, is indicated for the treatment of hyponatremia and fluid retention caused by heart failure. Developed originally by Otsuka Pharmaceutical Co., Ltd., Tolvaptan Tablets had an estimated market value of CNY 497 million in China during 2024, according to data from Menet. Huahai Pharmaceutical has invested CNY 9.51 million in the research and development of Tolvaptan Tablets. The company cautioned that the production and sales of the drug remain subject to policy and market uncertainties, and advised investors to exercise caution.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime